(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
The Kidney Transplant Program, part of the Division of Nephrology and Hypertension, is home to specialists with a wide variety of backgrounds and areas of focus. As a team, this diversity makes us better prepared to care for your child’s unique needs. Learn more about our faculty and staff.
Prasad Devarajan, MD Director, Division of Nephrology and Hypertension 513-636-4531 firstname.lastname@example.org
Director, Division of Nephrology and Hypertension
Medical Director, Stone Center
Director, Nephrology and Hypertension Clinical Laboratory
Louise M. Williams Endowed Chair
Professor, UC Department of Pediatrics
Clinical specialties: acute kidney injury, nephrotic syndrome, kidney stones
Visit the Devarajan Lab.
Premedical Studies: Bombay University, India, 1979.
MD: Bombay University, India, 1985.
Czech KA, Bennett M, Devarajan P. Distinct metalloproteinase excretion patterns in focal segmental glomerulosclerosis. Pediatr Nephrol. 2011 Jul 1.
Askenazi DJ, Koralkar R, Levitan EB, Goldstein SL, Devarajan P, Khandrika S, Mehta RL, Ambalavanan N. Baseline Values of Candidate Urine Acute Kidney Injury (AKI) Biomarkers Vary by Gestational Age in Premature Infants. Pediatr Res. 2011 Jun 3.
Abraham BP, Frazier EA, Morrow WR, Blaszak RT, Devarajan P, Mitsnefes M, Bryant JC, Sachdeva R. Cystatin C and neutrophil gelatinase-associated lipocalin as markers of renal function in pediatric heart transplant recipients. Pediatr Transplant. 2011 Apr 25.
Sundaram N, Bennett M, Wilhelm J, Kim MO, Atweh G, Devarajan P, Malik P. Biomarkers for early detection of sickle nephropathy. Am J Hematol. 2011 Jul;86(7):559-66.
Devarajan P, Krawczeski C. In reply to 'antifibrinolytic use during cardiac and hepatic surgery makes tubular proteinuria-based early biomarkers poor tools to diagnose perioperative acute kidney injury'. Am J Kidney Dis. 2011 Jun;57(6):960-1.
Piyaphanee N, Ma Q, Kremen O, Czech K, Greis K, Mitsnefes M, Devarajan P, Bennett MR. Discovery and initial validation of α 1-B glycoprotein fragmentation as a differential urinary biomarker in pediatric steroid-resistant nephrotic syndrome. Proteomics Clin Appl. 2011 Jun;5(5-6):334-42.
Li S, Krawczeski CD, Zappitelli M, Devarajan P, Thiessen-Philbrook H, Coca SG, Kim RW, Parikh CR; for the TRIBE-AKI Consortium. Incidence, risk factors, and outcomes of acute kidney injury after pediatric cardiac surgery: A prospective multicenter study. Crit Care Med. 2011 Jun;39(6):1493-1499.
Krawczeski CD, Woo JG, Wang Y, Bennett MR, Ma Q, Devarajan P. Neutrophil gelatinase-associated lipocalin concentrations predict development of acute kidney injury in neonates and children after cardiopulmonary bypass. J Pediatr. 2011 Jun;158(6):1009-1015.e1.
Basu RK, Devarajan P, Wong H, Wheeler DS. An update and review of acute kidney injury in pediatrics. Pediatr Crit Care Med. 2011 May;12(3):339-47.
Devarajan P. Biomarkers for the early detection of acute kidney injury. Curr Opin Pediatr. 2011 Apr;23(2):194-200.
Bradley P. Dixon, MD Pediatric Nephrologist, Division of Nephrology and Hypertension 513-636-4531 email@example.com
Pediatric Nephrologist, Division of Nephrology and Hypertension
Assistant Professor, UC Department of Pediatrics
DNA damage response; DNA repair; hyperosmolal microenvironments; atypical hemolytic uremic syndrome; thrombotic microangiopathies; complement-mediated renal diseases.
Visit the Dixon Lab.
Bradley Dixon, MD, joined the faculty in the Division of Nephrology and Hypertension at Cincinnati Children's in 2006. He has received support for his research from a William Cooper Procter Pediatric Research Award in 2006, a Child Health Research Career Development Award (K12) in 2009, and is currently funded by a K08 through the National Institute of Diabetes, Digestive and Kidney Diseases. Dr. Dixon’s research interests focus on the effects of hyperosmolal microenvironments such as the renal medulla and urinary bladder upon vital cellular processes such as the DNA damage response pathway and activation of cell cycle checkpoints and apoptosis. This research focus attempts to understand the susceptibility of the gastrointestinal tissues used in bladder reconstructions to carcinogenesis.
In addition to his basic science research interests, Dr. Dixon has a clinical research interest in thrombotic microangiopathies such as atypical hemolytic uremic syndrome (aHUS) and thrombotic thrombocytopenic purpura (TTP), and is an investigator in a number of clinical trials and registries for these diseases. Dr. Dixon is also involved in clinical research studying cystic kidney diseases such as autosomal dominant polycystic kidney disease (ADPKD).
BA: College of Wooster, Wooster, OH, 1995.
MD: University of Tennessee, Memphis, 1999.
Residency: Cincinnati Children's Hospital Medical Center, 1999-2002.
Chief Residency: Cincinnati Childrens Hospital, 2002-2003.
Fellowship: Cincinnati Childrens Hospital, 2003-2006.
Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, Davies SM, Pluthero FG, Lu L, Laskin BL. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013 Sep 19;122(12):2003-7.
Siroky BJ, Yin H, Babcock JT, Lu L, Hellmann AR, Dixon BP, Quilliam LA, Bissler JJ. Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress. Am J Physiol Renal Physiol. 2012 Sep 15;303(6):F831-44.
Dixon BP, Henry J, Siroky BJ, Chu A, Groen PA, Bissler JJ. Cell Cycle Control and DNA Damage Response of Conditionally Immortalized Urothelial Cells. PLoS ONE. 2011 Jan 28;6(1):e16595.
Dixon BP, Hulbert JC, Bissler JJ. Tuberous sclerosis complex renal disease. Nephron Exp Nephrol. 2011;118(1):e15-20.
Lo MM, Mo JQ, Dixon BP, Czech KA. Disseminated histoplasmosis associated with hemophagocytic lymphohistiocytosis in kidney transplant recipients. Am J Transplant. 2010 Mar;10(3):687-91.
Dixon BP, Chu A, Henry J, Kim R, Bissler JJ. Increased cancer risk of augmentation cystoplasty: possible role for hyperosmolal microenvironment on DNA damage recognition. Mutat Res. 2009 Nov 2;670(1-2):88-95.
Dixon BP, Lu L, Chu A, Bissler JJ. RecQ and RecG helicases have distinct roles in maintaining the stability of polypurine.polypyrimidine sequences. Mutat Res. 2008 Aug 25;643(1-2):20-8.
Dixon BP, McEnery P, Goebel J. Immunobiology of paediatric renal transplantation. Progress in Paediatric Urology. 2008;10:165-182.
Bissler JJ, Dixon BP. A mechanistic approach to inherited polycystic kidney disease. Pediatr Nephrol. 2005 May;20(5):558-66.
Dixon BP, Devarajan P, Mitsnefes M. Neonatal renovascular hypertension due to prenatal traumatic retroperitoneal hematoma. Pediatr Nephrol. 2005 May;20(5):670-2.
Stuart L. Goldstein, MD, FAAP, FNKF Director, Center for Acute Care Nephrology 513-803-3295 firstname.lastname@example.org
Director, Center for Acute Care Nephrology
Medical Director, Pheresis Service
Co-Medical Director, Heart Institute Research Core
Medical Director, Dialysis Unit
Acute kidney injury; continuous renal replacement therapy; cardio-renal syndrome; nephrotoxic medication associated morbidity
Stuart L. Goldstein, MD, has been an active investigator in the field of pediatric acute kidney injury (AKI) since 2000. Dr. Goldstein’s main research foci include: AKI epidemiology and outcomes, acute renal replacement therapy provision and investigation of novel urinary AKI biomarkers in the pediatric population. Dr. Goldstein has established a strong record of interdisciplinary and inter-institutional collaboration with cardiologists, intensivists and emergency center physicians, which is evidenced by his establishment and directing of the Prospective Pediatric Continuous Renal Replacement Therapy Registry from 2001 to 2012, and the Prospective Pediatric AKI Research Group (ppAKI-RG) in 2012. The ppAKI-RG is comprised of 39 centers from around the world with the goal of improving outcomes for the child with or at-risk for, AKI.
Dr. Goldstein has led initial efforts to develop a standardized definition for pediatric AKI, assess novel AKI biomarkers in heterogeneous populations, and conceiving and validating stratification tools to identify patients at risk for AKI. Building up these findings, Dr. Goldstein embarked on establishing the ppAKI-RG consortium to focus on multi-centered research studies that are dedicated to understanding and treating AKI in pediatric patients. Currently, the ppAKI-RG has initiated three major, and unprecedented, national and international studies (AWARE, NINJA and DIRECT) to reduce AKI and improve patient outcomes. Dr. Goldstein is also a recognized educator; he has developed the only pediatric specific acute care nephrology sub-specialty fellowship with graduates who are now leaders in the field of pediatric AKI.
MD: Columbia College of Physicians and Surgeons, New York, NY, 1990.
Residency: Baylor College of Medicine, Houston, TX.
Fellowship: Pediatric Nephrology, Children's Hospital, Boston, MA.
Inflammation, malnutrition and cardiac calcification in pediatric ESRD patients receiving dialysis. Principal Investigator. Casey Lee Ball Foundation. Jan 2010–Dec 2020.
Use of NGAL to Optimize Fluid Dosing, CRRT Initiation and Discontinuation in Critically Ill Children with Acute Kidney Injury. Principal Investigator. Gambro Renal Products. Nov 2011-Jan 2017.
Clinical Evaluation of the Prismaflex™ HF20 Set and Prismaflex™Control Unit Version 5.10 Software for Acute Continuous Renal Replacement Therapy (CRRT) in Children. Principal Investigator. Gambro Renal Products, Inc. Mar 2014–Mar 2016.
An Observational, Genomic Study of Patients with Drug Induced Kidney Injury. Principal Investigator. International SAE Consortium, LTD. May 2013-Dec 2015.
Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care. Principal Investigator. NICHD Pediatric Trials Network-POPS. Feb 2013–Feb 2017.
Antibiotic Safety in Infants with Complicated Intra-Abdominal Infections (SCAMP Trial). Principal Investigator. NICHD-2013-ABS01 Pediatric Trials Network. May 2014–Sep 2017.
Recombinant Erythropoietin Protects Against Kidney Disease. Principal Investigator. National Institutes of Health. Sep 2014–Aug 2019.
Reduction of Nephrotoxic Medication Associated Acute Kidney Injury in Children: Dissemination of a Successful Quality Improvement Project. Principal Investigator. Agency for Healthcare Research and Quality. Apr 2015–Mar 2018.
David K. Hooper, MD, MS Medical Director of Kidney Transplantation 513-636-4531 email@example.com
Medical Director of Kidney Transplantation
Nephrology; kidney transplantation; quality improvement
Jointly appointed in the Division of Nephrology and Hypertension and the James M. Anderson Center for Health Systems Excellence at Cincinnati Children’s Hospital Medical Center within the UC Department of Pediatrics, Dr. Hooper's aim is to improve clinical outcomes for pediatric kidney transplant recipients through research in personalized care and the design of reliable healthcare systems.
Dr. Hooper's research training includes a master's degree in clinical and translational research from the University of Cincinnati, in addition to advanced training in quality improvement methodology through the Quality Scholars in Healthcare Transformation program at Cincinnati Children’s.
Dr. Hooper's career focus is to combine clinical outcomes research with quality improvement to reliably prevent cardiovascular disease, the leading cause of long-term death and disability in pediatric transplant recipients.
MD: University of Utah, Salt Lake City, Utah, 2003.
Residency: Cincinnati Children's Hospital, Cincinnati, Ohio, 2006.
Chief Residency: Cincinnati Children's Hospital, Cincinnati, Ohio, 2007.
MS: University of Cincinnati, Cincinnati, Ohio, 2010.
Fellowship: Cincinnati Children's Hospital, Cincinnati Ohio, 2010; Quality Scholar in Healthcare Transformation, James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital, Cincinnati, Ohio, 2011.
Certification: Pediatrics, 2006.
Hooper DK, Kirby C, Margolis P, Goebel J. Reliable Individualized Monitoring Improves Cholesterol Control in Kidney Transplant Recipients. Pediatrics. 2013 Apr;131(4):e1271-9.
Hooper DK, Williams JC, Carle AC, Amaral S, Chand DH, Ferris ME, Patel HP, Licht C, Barletta GM, Bastian V, Mitsnesfes M, Patel UD. The Quality of Cardiovascular Disease Care and Formal Transition for Adolescents with Kidney Disease. Pediatr Nephrol. 2013 Jun;28(6):939-49.
Hooper DK, Fukuda T, Logan B, Gardiner R, Roy-Chaudhury A, Kirby C, Vinks A, Goebel J. Risk of Tacrolimus Toxicity in CYP3A5 Non-Expressors Treated with Intravenous Nicardipine After Kidney Transplantation. Transplantation. 2012 Apr;93(8):806-812.
Saldaña SN, Hooper DK, Froehlich TE, Campbell KM, Prows CA, Sadhasivam s, Nick TG, Seid M, Vinks AA, Glauser TA. Characteristics of Successful Recruitment in Prospective Pediatric Pharmacogenetic Studies. Clinical Therapeutics. 2011 Feb;15:88-95.
Hooper DK, Carle AC, Schuchter J, Goebel J. Interaction between tacrolimus and intravenous nicardipine in the treatment of post-kidney transplant hypertension at pediatric hospitals. Pediatr Transplant. 2011 Feb;15(1):88-95.
Kaplan HC, Brady PW, Dritz MC, Hooper DK, Linam WM, Froehle CM, Margolis P. The influence of context on quality improvement success in health care: a systematic review of the literature. Milbank Q. 2010 Dec;88(4):500-59.
Hooper DK. The Impact of CYP3A5 Genotype on the Interaction Between Tacrolimus and Intravenous Nicardipine in Kidney Transplant Recipients. University of Cincinnati. 2010 Aug 17.
Hooper DK, Hawkins JA, Fuller TC, Profaizer T, Shaddy RE. Panel-reactive antibodies late after allograft implantation in children. Ann Thorac Surg. 2005 Feb;79(2):641-4.
Raetz EA, Kim MK, Moos P, Carlson M, Bruggers C, Hooper DK, Foot L, Liu T, Seeger R, Carroll WL. Identification of genes that are regulated transcriptionally by Myc in childhood tumors. Cancer. 2003 Aug 15;98(4):841-53.
Lirazan MB, Hooper D, Corpuz GP, Ramilo CA, Bandyopadhyay P, Cruz LJ, Olivera BM. The spasmodic peptide defines a new conotoxin superfamily. Biochemistry. 2000 Feb 22;39(7):1583-8.
Elizabeth C. Jackson, MD Director, Healthy Bladder Clinic 513-636-4975 firstname.lastname@example.org
Director, Healthy Bladder Clinic
Associate Professor, UC Department of Pediatrics
Functional bladder disorders; neurogenic bladder; urolithiasis
Elizabeth C. Jackson, MD, is a pediatric nephrologist recognized in the need for bladder management. Dr. Jackson has recently discontinued her inpatient nephrology role and is currently focused on outpatient lower urinary tract management. She is the director of the Healthy Bladder Clinic at Cincinnati Children's. The Healthy Bladder Clinic cares for children with functional lower urinary tract disorders. There are more than 1200 visits per year to this clinic.
MD: University of Virginia, Charlottesville, VA, 1978.
Residency: Children's Hospital of Pittsburgh, Pittsburgh, PA, 1981.
Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 1984.
Certification: Pediatrics, 1983; Pediatric Nephrology, 1985.
Ivancić V, Defoor W, Jackson E, Alam S, Minevich E, Reddy P, Sheldon C. Progression of renal insufficiency in children and adolescents with neuropathic bladder is not accelerated by lower urinary tract reconstruction. J Urol. 2010 Oct;184(4 Suppl):1768-74.
DeFoor WR, Jackson E, Minevich E, Caillat A, Reddy P, Sheldon C, Asplin J. The risk of recurrent urolithiasis in children is dependent on urinary calcium and citrate. Urology. 2010 Jul;76(1):242-5.
DeFoor W, Clark C, Jackson E, Reddy P, Minevich E, Sheldon C. Risk factors for end stage renal disease in children with posterior urethral valves. J Urol. 2008 Oct;180(4 Suppl):1705-8; discussion 1708.
DeFoor W, Minevich E, Jackson E, Reddy P, Clark C, Sheldon C, Asplin J. Urinary metabolic evaluations in solitary and recurrent stone forming children. J Urol. 2008 Jun;179(6):2369-72.
DeFoor W, Asplin J, Jackson E, Jackson C, Reddy P, Sheldon C, Erhard M, Minevich E. Urinary metabolic evaluations in normal and stone forming children. J Urol. 2006 Oct;176(4 Pt 2):1793-6.
Defoor W, Asplin J, Jackson E, Jackson C, Reddy P, Sheldon C, Minevich E. Results of a prospective trial to compare normal urine supersaturation in children and adults. J Urol. 2005 Oct;174(4 Pt 2):1708-10.
Jensen S, Jackson EC, Riley L, Reddy S, Goebel J. Tacrolimus-based immunosuppression with steroid withdrawal in pediatric kidney transplantation -- 4-year experience at a moderate-volume center. Pediatr Transplant. 2003 7:119-124.
Strife CF, Prada AL, Clardy CW, Jackson E, Forristal J. Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis. J Pediatr. 1990 May;116(5):S98-102.
Mark M. Mitsnefes, MD, MS Director, Clinical and Translational Research Center 513-636-0125 email@example.com
Director, Clinical and Translational Research Center
Pediatric Nephrologist, Division of Nephrology
Nephrology with focus on chronic kidney disease and hypertension
Mark Mitsnefes, MD, MS, is an established clinical investigator with expertise in the area of understanding the development of risk factors for cardiovascular disease in children with chronic kidney disease. The long-term goal of his research is to define biologic targets for interventions to prevent and slow progression of cardiovascular disease in children with chronic kidney disease.
Dr. Misnefes has received numerous awards, including the Proctor Scolar Award (Cincinnati Children's Research Foundation), the Pediatrician Scientist Award (Children's Health Research Center, NIH), the Clinical Scientist Award (National Kidney Foundation), and has been ranked as one of the Best Doctors in America, 2007-2011.
MD: Gorky Medical Institute, Gorky, Russia, 1985.
Residency: Miami Children's Hospital, Miami, FL, 1997.
Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2000.
MS: Epidemiology and Biostatistics, University of Cincinnati, Cincinnati, OH, 2001.
Certifications: Educational Commission for Foreign Medical Graduates (ECFMG), 1995; Pediatrics, 1996; Pediatric Nephrology, 2001, 2008.
Mitsnefes M, Flynn J, Cohn S, Samuels J, Blydt-Hansen T, Saland J, Kimball T, Furth S, Warady B; CKiD Study Group. Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol. 2010 Jan;21(1):137-44.
Wilson AC, Mitsnefes MM. Cardiovascular disease in CKD in children: update on risk factors, risk assessment, and management. Am J Kidney Dis. 2009 Aug;54(2):345-60. Review.
Flynn JT, Mitsnefes MM, Pierce C, Cole SR, Parekh RS, Furth SL and Warady BA. Blood pressure in children with chronic kidney disease: Preliminary findings from chronic kidney disease in children cohort study. Hypertension. 2008;52(4):631-7
Weaver DJ Jr, Kimball T, Witt SA, Glascock BJ, Khoury PR, Kartal J, Mitsnefes MM. Subclinical systolic dysfunction in pediatric patients with chronic kidney disease. J Pediatr. 2008 Oct;153(4):565-9.
Weaver DJ Jr., Kimball TR, Knilans T, Mays WK, Knecht T, Gerdes YT, Witt S, Glascock BJ, Kartal J, Khoury PR, and Mitsnefes MM. Decreased maximal aerobic capacity in pediatric chronic kidney disease. J Am Soc Nephrol. 2008, 19(3):624-30.
Mitsnefes MM, Kimball TR, Kimball TR, Witt SA, Glascock BJ, Khoury PR, and Daniels SR. Abnormal carotid artery structure and function in children with successful renal transplant. Circulation. 2004; 110:97-101.
Mitsnefes MM, Kimball TR, Kartal J, Witt SA, Glascock B, Khoury PR, Daniels SR. Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: Role of calcium-phosphorus metabolism. J Am Soc Nephrol. 2005;16:2796-2803.
Mitsnefes MM, Kimball TR, Border WL, Witt SA, Glascock BJ, Khoury PR and Daniels SR. Impaired left ventricular diastolic function in children with chronic renal failure. Kidney Int. 2004;65(4):1461-1466.
Mitsnefes MM, Kimball TR, Witt SA, Glascock BJ, Khoury PR, and Daniels SR. Left ventricular mass and systolic performance in pediatric patients with chronic renal failure. Circulation. 2003;107:864-868
Mitsnefes MM, Daniels SR, Schwartz SM, Khoury P, Meyer RA, and Strife CF. Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol. 2000;14:898-902.
Edward J. Nehus, MD, MS Pediatric Nephrologist, Division of Nephrology 513-636-4531 firstname.lastname@example.org
Critical care nephrology; chronic kidney disease
Edward conducted and published a cross-sectional study which investigated the association of serum resistin with cardiovascular risk factors in children with chronic kidney disease. In addition, he recently published a study evaluating the outcomes steroid-avoidance protocols in pediatric kidney transplant recipients. He continues to be the primary investigator for ongoing studies that explore pharmacokinetic alterations in critically ill children receiving continuous renal replacement therapy.
MD: University of Toledo, Toledo, OH, 2002.
MS: University of Cincinnati, Cincinnati, OH, 2011.
Residency: Pediatrics, Nationwide Children’s Hospital, Columbus, OH.
Certification: Pediatrics, 2009.
Fellowship: Pediatric Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.
Nehus E, Goebel J, Abraham E. Outcomes of steroid-avoidance protocols in pediatric kidney transplant recipients. Am J Transplant. 2012 Dec;12(12):3441-8.
Nehus E, Furth S, Warady B, Mitsnefes M. Correlates of resistin in children with chronic kidney disease: the chronic kidney disease in children cohort. J Pediatr. 161(2): 276-80, 2012.
Nehus E, Goebel J, Mitsnefes M, Lorts A, Laskin B. Intensive hemodialysis for cardiomyopathy associated with end-stage renal disease. Pediatr Nephrol. 26: 1909-12, 2011.
Nehus E, Devarajan P. Acute kidney injury: AKI in kidney transplant recipients—here to stay. Nat Rev Nephrol. 8:198-199, 2012.
C. Frederic Strife, MD Professor Emeritus email@example.com
Emeritus, UC Department of Pediatrics
MD: College of Medicine and Dentistry of New Jersey, 1968.
Residency: Pediatrics, Children's Hospital Medical Center, Cincinnati, OH.
Fellowship: Nephrology, Children's Hospital Medical Center, Cincinnati, OH.
Certification: Pediatrics, 1973; Pediatric Nephrology, 1976.
Calvo-Garcia MA, Campbell KM, O'Hara SM, Khoury P, Mitsnefes MM, Strife CF. Acquired renal cysts after pediatric liver transplantation: association with cyclosporine and renal dysfunction. Pediatr Transplant. 2008 Sep;12(6):666-71.
Vo NJ, Hammelman BD, Racadio JM, Strife CF, Johnson ND, Racadio JM. Anatomic distribution of renal artery stenosis in children: implications for imaging. Pediatr Radiol. 2006 Oct;36(10):1032-6.
Brunner HI, Bishnoi A, Barron AC, Houk LJ, Ware A, Farhey Y, Mongey AB, Strife CF, Graham TB, Passo MH. Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus. Lupus. 2006;15(4):198-206.
Mitsnefes MM, Subat-Dezulovic M, Khoury PR, Goebel J, Strife CF. Increasing incidence of post-kidney transplant anemia in children. Am J Transplant. 2005 Jul;5(7):1713-8.
Omoloja AA, Kumar K, Crawford AH, Strife CF. Epiphyseal stapling and recombinant human growth hormone for correction of genu valgum in children with chronic renal insufficiency. J Pediatr Orthop. 2003 Sep-Oct;23(5):639-42.
Lande MB, Gullion C, Hoss RJ, Gauthier B, Shah B, Leonard MB, Bonilla-Felix M, Nash M, Roy S, Strife CF, Arbus G. Long versus standard initial steroid therapy for children with the nephrotic syndrome. A report from the Southwest Pediatric Nephrology Study. Pediatr Nephrol. 2003;18:342-6.
Chand DH, Rhoades T, Poe SA, Kraus S, Strife CF. Incidence and severity of vesicoureteral reflux in children related to age, gender, race and diagnosis. J Urol. 2003;170:1548-1550.
Chand DH, Poe SA, Strife CF. Venous pressure monitoring does not accurately predict access failure in children. Pediatr Nephrol. 2002;17:765-770.
Mitsnefes MM, Daniels SR, Schwartz SM, Khoury P, Strife CF. Changes in left ventricular mass in children and adolescents during chronic dialysis. Pediatr Nephrol. 2001 Apr;16(4):318-23.
Mitsnefes MM, Daniels SR, Schwartz SM, Meyer RA, Khoury P, Strife CF. Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol. 2000 Sep;14(10-11):898-902.
Rene G. Van De Voorde III, MD Pediatric Nephrologist, Division of Nephrology 513-636-4531 firstname.lastname@example.org
Dialysis; primarily infant dialysis; chronic kidney disease; acute kidney injury; hypertension
MD: Vanderbilt University, Nashville, TN.
Residency: Pediatrics, Cincinnati Children's Hospital, Cincinnati, OH.
Chief Resident: Pediatrics, Cincinnati Children's Hospital, Cincinnati, OH.
Fellowship: Pediatric Nephrology, Cincinnati Children's Hospital, Cincinnati, OH.
Certification: Pediatrics, 2003; Pediatric Nephrology, 2008.
VanDeVoorde RG, Mitsnefes MM. Hypertension in chronic kidney disease in children. Advances in Chronic Kidney Disease. 2011.
Krawczeski CD, Vandevoorde RG, Kathman T, Bennett MR, Woo JG, Wang Y, Griffiths RE, Devarajan P. Serum cystatin C is an early predictive biomarker of acute kidney injury after pediatric cardiopulmonary bypass. Clin J Am Soc Nephrol. 2010 Sep;5(9):1552-7.
Alon US, VandeVoorde RG. Beneficial effect of cinacalcet in a child with familial hypocalciuric hypercalcemia. Pediatr Nephrol. 2010 Sep;25(9):1747-50.
Bredrup C, Matejas V, Barrow M, Bláhová K, Bockenhauer D, Fowler DJ, Gregson RM, Maruniak-Chudek I, Medeira A, Mendonça EL, Kagan M, Koenig J, Krastel H, Kroes HY, Saggar A, Sawyer T, Schittkowski M, Swietliński J, Thompson D, VanDeVoorde RG, Wittebol-Post D, Woodruff G, Zurowska A, Hennekam RC, Zenker M, Russell-Eggitt I. Ophthalmological aspects of Pierson syndrome. Am J Ophthalmol. 2008 Oct;146(4):602-611.
VanDe Voorde RG, Mitsnefes MM. Ambulatory blood pressure monitoring: a quest for truth. Pediatr Transplant. 2007 Feb;11(1):10-3.
Wuhl E, Kogan J, Zurowska A, Matejas V, VanDeVoorde RG, Aigner T, Wendler O, Lesniewska I, Bouvier R, Reis A, Weis J, Cochat P, Zenker M. Neuro-developmental deficits in Pierson (microcoria-congenital nephrosis) Syndrome. American Journal of Medical Genetics (A). 2007;143(4):311-9.
VanDeVoorde RG, Barletta G, Chand D, Dresner IG, Lane J, Leiser J, Lin JJ, Pan CG, Patel H, Valentini RP, Mitsnefes MM. Status of Blood Pressure Control in Children on Maintenance Hemodialysis: The Midwest Pediatric Nephrology Consortium (MWPNC) Study. Pediatric Nephrology. 2007;22(4):547-53.
VanDeVoorde R, Witte D, Kogan J, Goebel J. Pierson Syndrome: A Novel Cause of Congenital Nephrotic Syndrome. Pediatrics. 2006;118(2):E1-5.
Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared with Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subjects with Dialysis dependent Chronic Kidney Disease. Site Co-investigator. AMAG Pharmaceutical. Apr 2011 - present.
Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared with Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subjects with Non-dialysis dependent Chronic Kidney Disease. Site-Principal Investigator. AMAG Pharmaceuticals. Apr 2011 - present.
A Randomized, Open-label, Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCI in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis. Principal Investigator. AMGEN. Jul 2014 – present.
An Open-label, Single-arm Study to Assess the Safety and Tolerability of Cinacalcet HCI in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Years with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Dialysis. Principal Investigator. NAPRTCS. Mar 2012 – Mar 2016.
Maria H. Alonso, MD Surgical Director, Kidney Transplant Program 513-636-4371 email@example.com
Surgical Director, Kidney Transplant Program
Co-Surgical Director, Intestinal Transplant Surgery
Associate Professor, UC Department of Surgery
Liver, kidney transplantation; hepatobiliary surgery; minimally invasive surgery; trauma
MD: University of Pennsylvania School of Medicine, Philadelphia, PA, 1982.
Residency: Surgery, Eastern Virginia Graduate School of Medicine, Norfolk, VA.
Fellowship: Trauma / Critical Care, Maryland Institute for Emergency Medical Services Systems, Baltimore, MD; Trauma / Burn, Children's National Medical Center, Washington, D.C.; Pediatric Surgery, Children's Mercy Hospital, Kansas City, MO; Transplantation, University of Cincinnati College of Medicine, Cincinnati, OH.
Certification: Surgery, 1999; Pediatric Surgery, 2001; Surgical Critical Care, 2001.
Jaimie D. Nathan, MD Surgical Director, Intestinal Transplant Program 513-636-4371 firstname.lastname@example.org
Surgical Director, Intestinal Transplant Program
Surgical Director, Pancreas Care Center
Assistant Professor, UC Department of Surgery
UC Department of Pediatrics
Hepatobiliary and pancreatic disease; liver, kidney, and intestinal transplantation; pediatric surgical oncology; neonatal surgery; minimally invasive surgery
BS: Yale University, New Haven, CT, 1993.
MD: Yale University, New Haven, CT, 1998.
Residency: General Surgery, Duke University Medical Center, Durham, NC, 1998-2000 and 2002-2005.
Surgical Research Fellowship: Duke University Medical Center, Durham, NC, 2000-2002.
Pediatric Surgery Fellowship: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2005-2007.
Transplant Surgery Fellowship: University of Cincinnati, Cincinnati, OH, 2007-2009.
Certification: American Board of Surgery, General Surgery, 2007; American Board of Surgery, Pediatric Surgery, 2008; American Society of Transplant Surgeons Certification, 2009.
Prada CE, Kaul A, Hopkin RJ, Page KI, Nathan JD, Bartholomew DW, Cohen MB, Heubi JE, Leslie ND, Burrow TA. Recurrent pancreatitis in ornithine transcarbamylase deficiency. Mol Genet Metab. 2012 Aug;106(4):482-484.
Bondoc AJ, Taylor JA, Alonso MH, Nathan JD, Wang Y, Balistreri WF, Bezerra JA, Ryckman FC, Tiao GM. The beneficial impact of revision of Kasai portoenterostomy for biliary atresia: an institutional study. Ann Surg. 2012 Mar;255(3):570-576.
Shin CR, Nathan J, Alonso M, Yazigi N, Kocoshis S, Tiao G, Davies SM. Incidence of acute and chronic graft-versus-host disease and donor T-cell chimerism after small bowel or combined organ transplantation. J Pediatr Surg. 2011 Sep;46(9):1732-1738.
Vigna SR, Shahid RA, Nathan JD, McVey DC, Liddle RA. Leukotriene B4 mediates inflammation via TRPV1 in duct obstruction-induced pancreatitis in rats. Pancreas. 2011 Jul;40(5):708-714.
Nathan JD, Romac J, Peng RY, Peyton M, Rockey DC, Liddle RA. Protection against chronic pancreatitis and pancreatic fibrosis in mice overexpressing pancreatic secretory trypsin inhibitor. Pancreas. 2010 Jan;39(1):e24-30.
Ryckman FC, Bucuvalas JC, Nathan J, Alonso M, Tiao G, Balistreri WF. Outcomes following liver transplantation. Semin Pediatr Surg. 2008 May;17(2):123-30.
Follmar KE, Condron SA, Turner II, Nathan JD, Ludwig KA. Treatment of metronidazole-refractory Clostridium difficile enteritis with vancomycin. Surg Infect. 2008 9:195-200.
Nathan JD, Rudolph JA, Kocoshis SA, Alonso MH, Ryckman FC, Tiao GM. Isolated liver and multivisceral transplantation for total parenteral nutrition-related end-stage liver disease. J Pediatr Surg. 2007 Jan;42(1):143-7.
Patel MB, Nathan JD, Frush DP, Rice HE. Nonoperative management of asymptomatic traumatic pulmonary hernia in a young child. J Trauma. 2007 62:234-235.
Nathan JD, Romac J, Peng RY, Peyton M, MacDonald RJ, Liddle RA. Transgenic expression of pancreatic secretory trypsin inhibitor-I ameliorates secretagogue-induced pancreatitis in mice. Gastroenterology. 2005 128:717-727.
Frederick C. Ryckman, MD Sr. Vice President, Medical Operations 513-636-4371 email@example.com
Sr. Vice President, Medical Operations
UC Department of Surgery
Transplantation; liver; kidney transplantation; small intestine; biliary disease; Extracorporeal membrane oxygenation (ECMO); minimally invasive surgery; chest wall abnormalities
Frederick C. Ryckman, MD, is clinical director of the Pediatric General and Thoracic Surgery Division.
Dr. Ryckman is also vice president of System Capacity & Perioperative Operations.
Dr. Ryckman is also a pediatric surgeon at the Cincinnati Fetal Center.
BS: Lyman Briggs College of Science and Mathematics, Michigan State University, East Lansing, MI, 1969 to 1973.
MD: University of Michigan Medical School, Ann Arbor, MI, 1977.
Residency: University of Florida Medical Center, Gainesville, FL, 1977 to 1982.
Fellowship: Pediatric Surgery, Children's Hospital Medical Center, Cincinnati, OH, 1982 to 1984.
Certification: National Board of Medical Examiners, 1977; American Board of Surgery, 1983; recertification, 1993; Certificate of Special Competence in Pediatric Surgery, 1986; recertification, 1993.
Wagner LM, Gelfand MJ, Laor T, Ryckman FC, Al-Ghawi H, Bove KE. A Welcome Surprise: Nodular Fasciitis Presenting as Soft Tissue Sarcoma. J Pediatr Hematol Oncol. 2010 Oct 21.
Taylor JA, Ryckman FC. Management of small bowel volvulus around feeding Roux-en-Y limbs. Pediatr Surg Int. 2010 Apr;26(4):439-42.
Ryckman FC, Yelton PA, Anneken AM, Kiessling PE, Schoettker PJ, Kotagal UR. Redesigning intensive care unit flow using variability management to improve access and safety. Jt Comm J Qual Patient Saf. 2009 Nov;35(11):535-43.
Rattan AS, Laor T, Ryckman FC, Brody AS. Pectus excavatum imaging: enough but not too much. Pediatr Radiol. 2010 Feb;40(2):168-72.
Propst EJ, Lin EP, Istaphanous GK, Boesch RP, Ryckman FC, Cotton RT, Rutter MJ. Management of traumatic tracheobronchial separation in a teenager using a fabricated extra-long endotracheal tube. Int J Pediatr Otorhinolaryngol. 2009 Aug;73(8):1163-7.
Ryckman FC, Schoettker PJ, Hays KR, Connelly BL, Blacklidge RL, Bedinghaus CA, Sorter ML, Friend LC, Kotagal UR. Reducing surgical site infections at a pediatric academic medical center. Jt Comm J Qual Patient Saf. 2009 Apr;35(4):192-8.
Dickie B, Dasgupta R, Nair R, Alonso MH, Ryckman FC, Tiao GM, Adams DM, Azizkhan RG. Spectrum of hepatic hemangiomas: management and outcome. J Pediatr Surg. 2009 Jan;44(1):125-33.
Sparling KW, Ryckman FC, Schoettker PJ, Byczkowski TL, Helpling A, Mandel K, Panchanathan A, Kotagal UR. Financial impact of failing to prevent surgical site infections. Qual Manag Health Care. 2007 Jul-Sep;16(3):219-25.
Nathan JD, Rudolph JA, Kocoshis SA, Alonso MH, Ryckman FC, Tiao GM. Isolated liver and multivisceral transplantation for total parenteral nutrition-related end-stage liver disease. J Pediatr Surg. 2007 Jan;42(1):143-7.
Greg M. Tiao, MD Richard and Geralyn Azizkhan Chair in Pediatric Surgery 513-636-4371 firstname.lastname@example.org
Richard and Geralyn Azizkhan Chair in Pediatric Surgery
Surgical Director, Liver Transplantation
Associate Director, Pediatric Surgery Fellowship
Professor, UC Department of Surgery
As a pediatric surgeon and a transplant surgeon, Dr. Tiao is involved in the care of children afflicted with biliary atresia from the time of presentation and diagnosis to the initial Kasai portoenterostomy to the liver transplant, when necessary. He sees the many challenges children and their families experience when diagnosed with this life threatening disease process. From that perspective, defining the basis of this disease process such that therapeutic strategies can be developed eliminating these complex interventions is his career goal. His short term goal is to develop an independent research laboratory investigating the pathogenesis of virus induced biliary atresia specifically seeking to determine the mechanistic basis of this disease so that new treatment strategies can be developed to salvage the native liver.
Dr. Tiao's overarching hypothesis is that biliary atresia results from the infection of cholangiocytes by a virus triggering immune-mediated biliary obstruction. His focus is to determine the mechanisms used by RRV to infect cholangiocytes, how RRV undergoes replication within the cholangiocyte, and how infected cholangiocytes modify the microenvironment, activating the immune system resulting in biliary obstruction. Determination of the mechanistic basis of these inter-related events is essential to understanding the pathogenesis of virus induced BA. By focusing on the basis for the viral insult in the initiation of biliary atresia, he has defined an area of independence from Dr Jorge Bezerra, his primary research mentor.
BS: Northwestern University, Evanston, IL, 1986.
MD: University of Illinois, Chicago, IL, 1990.
Residency: Loyola University, Maywood, IL, 1991-1992; Senior Resident, Department of Surgery, University of Cincinnati, Cincinnati, OH, 1995-1997;Chief Resident, Department of Surgery, University of Cincinnati, Cincinnati, OH, 1997-1998.
Fellowships: Research Fellow, University of Cincinnati, Cincinnati, OH, 1992-1995; Transplant Surgery Fellow, University of Cincinnati, Cincinnati, OH, 2000-2002;Pediatric Surgery Fellow, Los Angeles Children's Hospital, Los Angeles, CA, 1998-2000.
Certification: Pediatric Surgeon, 2000; Transplant Surgeon, 2002.
Coots A, Donnelly B, Mohanty S, Tiao G. Rotavirus Infection of Human Cholangiocytes Parallels the Murine Model of Biliary Atresia. J Surg Res. 2012 Oct;177(2):275-81. 2012.
Meyers RL, Tiao GM, Dunn SP, Langham Jr, MR. Liver transplantation in the management of unresectable hepatoblastoma in children. Front Biosci (Elite Ed). 2012 Jan;E4:1293-302.
Shin CR, Nathan J, Alonso M, Yazigi N, Kocoshis S, Tiao G, Davies SM. Incidence of acute and chronic graft-versus-host disease and donor T-cell chimerism after small bowel or combined organ transplantation. J Pediatr Surg. 2011;46:1732-8.
Fernandez KS, Baum R, Fung B, Yeager N, Leonis MA, Wagner LM, Tiao G, Ross ME. Chemoresistant Hepatoblastoma in a Patient with Mosaic Trisomy 18 Treated with Orthotopic Liver Transplantation. Peditr Blood Cancer. 2011;56:498-500.
Superina R, Magee J, Brandt M, Healey P, Tiao G, Ryckman F, Karrer F, Iyer K, Fecteau A, West K, Burns R, Flake A, Hammin L, Lowell J, Dillon P, Columbani P, Ricketts R, Yun L, Moore J, Kasper W. Childhood Liver Research and Education Network. AnnSurg. 2011.
Bondoc A, Taylor J, Alonso M, Nathan, J, Wang Y, Balistreri W, Bezerra J, Ryckman F, Tiao G. The Beneficial Impact of Revision of Kasai Portoenterostomy for Biliary Atresia: An Institutional Study. AnnSurg. 2012;255(3):570-6.
Wang W, Donnelly B, Bondoc A, Mohanty SK, McNeal M, Ward R, Sestak K, Zheng S, Tiao G. The rhesus rotavirus gene encoding VP4 is a major determinant in the pathogenesis of biliary atresia in newborn mice. J Virol. 2011 Sep;85(17):9069-77.
Jafri M, Donnelly B, Bondoc A, Allen S, Tiao G. Cholangiocyte secretion of chemokines in experimental biliary atresia. J Pediatr Surg. 2009;44(3):500-7.
Bondoc AJ, Jafri MA, Donnelly B, Mohanty SK, McNeal MM, Ward, RL, Tiao GM. Prevention of the murine model of biliary atresia after live rotavirus vaccination of dams. J Pediatr Surg. 2009;44(8):1479-90.
The Molecular Determinants of Virus Induced Biliary Induced Biliary Asteria. Principal Investigator. Apr 2011 - Mar 2016.
Nycomed Liver Trial. Principal Investigator. 2012-present.TC-2402-040-SP.
Sondra L. Weingartner, MSW, LISW-S
Social Worker, Comprehensive Epilepsy Center 513-636-8228 email@example.com
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center